FDA Peptide Warning Letters Tracker
In short: the FDA keeps warning sellers who label peptides "for research use only" but sell them for people. The FDA says that label does not make it legal when the website shows the products are meant for people, for example by selling bacteriostatic water to mix shots.
| Date | Company | Products named | Letter |
|---|---|---|---|
| Aug 24, 2026 | Royal Peptides LLC | Tirzepatide, semaglutide, retatrutide, SS-31, PT-141, tesamorelin, "Bimorelin" | fda.gov |
| Aug 24, 2026 | NuScience Peptides LLC | Tirzepatide, semaglutide, retatrutide, survodutide, mazdutide, PT-141, tesamorelin, BAC water | fda.gov |
| Aug 24, 2026 | Peak Performance Peptides | Retatrutide, semaglutide, SS-31, PT-141, tesamorelin, BAC water | fda.gov |
| Mar 31, 2026 | Gram Peptides | Retatrutide, tirzepatide, BAC water | fda.gov |
| Mar 31, 2026 | Lovega LLC dba Pink Pony Peptides | "GLP-2 TZ", "GLP-3 RT", BAC water | fda.gov |
What these letters mean for you
- The FDA calls these products "unapproved new drugs."
- Their quality is unknown. Ask your doctor about approved options.
- A warning letter is not a court ruling. Companies can answer the FDA.
This list is not complete. We add letters after we check them on fda.gov. Check any peptide with our FDA Status Checker.